Results 241 to 250 of about 98,417 (285)
SNHG10 promotes tumorigenesis through the EGFR/AKT/ERK/mTOR and miR-150-5p/VEGF-A axis, along with gemcitabine resistance in pancreatic ductal adenocarcinoma. [PDF]
Cell Death DiscovPandya G +13 more
europepmc +1 more source
CEACAM6: A potential prognostic biomarker and therapeutic target in cholangiocarcinoma
Clinical and Translational Discovery, Volume 6, Issue 3, June 2026.
Jia‐Qi Guo +3 more
wiley +1 more source
Plenary Abstracts Session & Oral Presentations
HemaSphere, Volume 10, Issue S1, June 2026.
wiley +1 more source
Reactions Weekly, 2009 Gemcitabine (2',2'-difluorodeoxy- cytidine, dFdC) is an analog of deoxycytidine. It is transformed to the active triphosphate (dFdCTP) after intracellular phosphorylation.
Alinari L. +10 more
core +4 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Seminars in Oncology, 2001
Newer agents and combinations are needed in order to improve current results in the treatment of ovarian cancer. Gemcitabine (Gemzar; Eli Lilly and Company, Indianapolis, IN) is a novel agent with a unique mechanism of action that has shown consistent activity as a single-agent in platinum-resistant ovarian cancer, with remission rates of nearly 20 ...
M, Orlando, M, Mandachain
openaire +2 more sources
Newer agents and combinations are needed in order to improve current results in the treatment of ovarian cancer. Gemcitabine (Gemzar; Eli Lilly and Company, Indianapolis, IN) is a novel agent with a unique mechanism of action that has shown consistent activity as a single-agent in platinum-resistant ovarian cancer, with remission rates of nearly 20 ...
M, Orlando, M, Mandachain
openaire +2 more sources